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Background and purpose: Reported plan quality improvements with autoplanning of radiotherapy of the
prostate and seminal vesicles are poor. A system for automated multi-criterial planning has been
validated for this treatment in a large international multi-center study. The system is configured with
training plans using a mechanism that strives for quality improvements relative to those plans.
Material and methods: Each of the four participating centers included thirty manually generated clinical
Volumetric Modulated Arc Therapy prostate plans (manVMAT). Ten plans were used for autoplanning
training. The other twenty were compared with an automatically generated plan (autoVMAT). Plan eval-
uations considered dosimetric plan parameters and blinded side-by-side plan comparisons by clinicians.
Results: With equivalent Planning Target Volume (PTV) V95%, D2%, D98%, and dose homogeneity autoVMAT
was overall superior for rectum with median differences of 3.4 Gy (p < 0.001) in Dmean, 4.0% (p < 0.001) in
V60Gy, and 1.5% (p = 0.001) in V75Gy, and for bladder Dmean (0.9 Gy, p < 0.001). Also the clinicians’ plan
comparisons pointed at an overall preference for autoVMAT. Advantages of autoVMAT were highly
treatment center- and patient-specific with overall ranges for differences in rectum Dmean and V60Gy of
[4,12] Gy and [2,15]%, respectively.
Conclusion: Observed advantages of autoplanning were clinically relevant and larger than reported in the
literature. The latter is likely related to the multi-criterial nature of the applied autoplanning algorithm,
with for each center a dedicated configuration that aims at plan improvements relative to its (clinical)
training plans. Large variations among patients in differences between manVMAT and autoVMAT point
at inconsistencies in manual planning.
 2018 Published by Elsevier B.V. Radiotherapy and Oncology xxx (2018) xxx–xxxAlready in 1998 Reinstein et al. [1] investigated automation of
inverse planning of radiotherapy. For six prostate cancer patients
they could generate high quality Intensity-Modulated Radiation
Therapy (IMRT) plans using a fixed planning template. Several
papers have now reported on systematic comparisons of fully
automatically generated clinically deliverable IMRT or Volumetric
Modulated Arc Therapy (VMAT) plans with manually generated
plans for treatment of the prostate and seminal vesicles [2–13].In eight of the twelve studies autoplanning was knowledge-
based, i.e. using a model that describes relationships between dose
and anatomy in patients treated previously using manual planning.
In five of these studies organ-at-risk (OAR) Dose Volume
Histograms (DVH) were predicted and used to automatically gen-
erate plans for test patients [4,5,8,10,13]. In one study the full dose
distribution was predicted [7]. In two studies [2,3] automated
planning was based on the beam geometry, the fluence map, and
the constraints and weights of a reference case in a plan database
with similar Beam’s Eye View contours as the test patient. Methods
of autoplanning not based on a prediction model as derived from a
database of previously treated plans included automated apriori
multi-criterial plan optimization (aprioriMCO) [6], automatedational
2 Multi-center validation of multi-criterial autoplanningiterative constraint adaptation [9], use of a particle swarm
optimizer for automated selection of objective function weights,
and automated iterative fine-tuning of cost functions [12]. Only
in two studies were plans compared for >50 patients. Reported
improvements in plan qualitywith autoplanningwere overall mod-
est. The only report on a multi-center comparison of manual- vs.
autoplanning for prostate cancer is by Schubert et al. [10], using a
DVH prediction model generated in a single center which was
validated in six other centers. Automatically generated plans had
reductions in rectum and bladder Dmean of 0.6 and 0.8 Gy respec-
tively, while for both OARs high doses were worse for autoVMAT.
In this study we have investigated an aprioriMCO autoplanning
system [6,14,16,17]. While in a posteriori MCO a Pareto-frontier of
plans is upfront generated for selection of the preferred treatment
plan by a planner afterward, in aprioriMCO a single Pareto-optimal
plan is directly and automatically generated for each new patient,
featuring clinically favorable trade-offs between all treatment
goals. Configuration of the algorithm for a treatment site has an
intrinsic mechanism for plan quality improvement relative to
training plans [6,16,17]. In that sense there is a clear difference
with knowledge-based planning that focuses on reproducing the
plan quality of previously treated patients.
In a previous study [6] aprioriMCO autoplanning was tested for
prostate cancer by comparison with manual planning performed
by the most competent manual planner in the center whose task
was to generate the best possible manual plans without any con-
straint in planning time. Quality differences between manVMAT
and autoVMAT were negligible.
This paper describes a large international multi-center valida-
tion of aprioriMCO comparing autoVMAT and manVMAT plans
for prostate cancer. In contrast to [6] manVMAT plans were gener-
ated with routine clinical planning, so not by the best planner
without planning time restrictions. The aprioriMCO algorithm
was configured for each center separately, aiming at the best auto-
VMAT quality for the center’s treatment approach with an explicit
drive to improve on the quality of the training plans. Plan quality
evaluations considered dosimetric plan parameters and side-by-
side comparisons of plans by treating clinicians who were blinded
for the origin of the plans (autoVMAT or manVMAT). In line with
general clinical practice, in these clinicians’ comparisons all
trade-offs in the plans (doses in PTV and OARs, conformity, etc.)
are simultaneously considered for an overall judgement. By includ-
ing a large number of patients from four centers we could investi-
gate in detail differences between centers and patients in the
potential of autoplanning.Materials and methods
Patients and clinical planning
In each of the participating centers in Mannheim, Florence,
Leeds and Vienna (referred to by randomly assigned letters A, B,
C, and D) 30 anonymized clinical manVMAT plans recently deliv-
ered on an Elekta linac (Elekta AB, Stockholm, Sweden) were
included in the study. The prostate and seminal vesicles were irra-
diated. Plans were generated with manual planning using the Mon-
aco Treatment Planning System (TPS) (Elekta AB, Stockholm,
Sweden). A single plan was used in A, B and D, while in center C
patients were treated with a sequential boost technique. For the
latter center, we investigated plans for delivery of the first 60 Gy.
In center A, a simultaneous integrated boost technique was used
for delivery of 76 Gy to the prostate and 68.8 Gy to the seminal
vesicles in 37 fractions. In centers B and D the prostate and seminal
vesicles were treated up to 78 Gy in 39 fractions, and 80 Gy in 40
fractions respectively. In B patients were treated with an endo-
rectal balloon.Please cite this article in press as: Heijmen B et al. Fully automated, multi-cri
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The Erasmus-iCycle/Monaco system used in this study for apri-
oriMCO autoplanning has been extensively described before [6,14–
17]. Input for each plan generation is a tumor site specific wish-list
containing hard planning constraints and treatment objectiveswith
assigned priorities used to steer the multi-criterial planning.
Automatically generated plans were clinically deliverable. The apri-
oriMCO system and the procedure for wish-list configuration are
summarized in Figs. E1a and E1b of the Supplementary material.
In each center ten randomly selectedmanVMAT plans (‘training’
patients) were used for wish-list tuning (see Tables E2a–E2d of the
Supplementary material for final wish-lists). The final wish-list was
used for autoVMAT plan generation for the remaining 20 ‘evalua-
tion’ patients (open-loop validation). In each center the Monaco
(Elekta AB, Stockholm, Sweden) version used for final automatic
plan generation was the same as the version used for manual plan-
ning. Also the number of arcs, control points, and theminimum seg-
ment size were the same for manual- and autoplanning. Details are
provided in Table E3a of the Supplementary material.
In each center autoplanning was completely free from human
interference and based on the same manually generated contours
as used for manual planning.
Automated vs. manual planning – dosimetric plan quality
AutoVMAT and manVMAT plans were compared by assessing
differences in PTV V95% (coverage), D2% (near-maximum dose),
D98% (near-minimum dose), and ((D2%–D98%)/(prescribed dose)) *
100 (homogeneity index, HI), rectum Dmean, rectum V60Gy, rectum
V75Gy, bladder Dmean, and bladder V65Gy. Differences in OAR mean
doses represent overall unweighted changes in delivered dose.
The use of rectum V60Gy, and V75Gy and bladder V65Gy reflects the
concern of the clinicians in this study for high doses in these OARs,
with an accent on high rectum dose.
The clinicians first assessed the clinical acceptability of all auto-
VMAT and manVMAT plans separately (for manVMAT: consistency
check as these plans had already been clinically approved for
delivery). For this purpose the 20 autoVMAT and 20 manVMAT
evaluation plans were individually loaded in the TPS. Pseudo-
randomization was used to establish the plan order with correc-
tions to guarantee that in between the autoVMAT and manVMAT
plan of a patient there were at least two plans of other patients.
For the subsequent blinded side-by-side plan comparisons for the
20 evaluation patients scoring was performed using a visual analog
scale (Fig. E3b of the Supplementary material).
In centers A–C blinded scoring was performed by one clinician
while in center D scoring was performed by two clinicians.Modulation degree, total MU and estimated treatment time
Auto- andmanVMAT plans were compared regarding the degree
ofmodulation, the total number ofMU and the estimated treatment
time. The degree of modulation as reported by the TPS was defined
as the sum of the MU of all segments divided by the sum over all
segments of ((segment area  segment MU)/ total beam area).Deliverability of autoVMAT plans
To verify deliverability of generated autoVMAT prostate plans
center A performed QA measurements with the Delta4 system
(Scandidos, Uppsala, Sweden).Statistics
All differences between autoVMAT and manVMAT were evalu-
ated using paired two-sided Wilcoxon signed-rank tests to assessterial planning for Volumetric Modulated Arc Therapy – An international
i.org/10.1016/j.radonc.2018.06.023
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formed with SPSS version 24.Results
For the 80 evaluation patients there was no difference between
manVMAT and autoVMAT in median PTV V95% (98.5 vs. 98.4%,
p = 0.6), median PTV D2% (79.5 vs. 80.0 Gy, p = 0.9), median PTV
D98% (73.3 vs. 73.5 Gy, p = 0.9) and median HI (7.7 vs. 8.1%,
p = 0.8), while rectum dose was substantially reduced with
autoVMAT (median reductions/ranges: 3.4/[3.7,12.2] Gy
(p < 0.001), 4.0/[2.3,15.0]% (p < 0.001), and 1.5/[3.5,6.7]%
(p < 0.001) for Dmean, V60Gy, and V75Gy, respectively). There was also
a small advantage for autoVMAT in median bladder Dmean (0.9/
[10.1,10.0] Gy, p < 0.001) while the small difference in bladder
V65Gy was not significant (0.4/[14.7,15.1], p = 0.3). Fig. 1 shows
frequency histograms for the observed differences.
While overall PTV coverage was equal, two centers had a small
but (borderline) significant advantage for autoVMAT (median
differences 0.3% and 1.0%). For the other two coverage was higher
for manVMAT (0.4% and 0.8%). In all centers rectum Dmean was
lower for autoVMAT but for center C the difference was only
0.1 Gy (not significant) while for A and D this went up to 5.6 Gy
and 8.0 Gy, respectively. In the latter centers this was accompaniedFig. 1. Histograms showing the frequencies of observed differences between manual pla
rectum V60Gy (c), rectum V75Gy (d), bladder Dmean (e) and bladder V65Gy (f). A, B, C, and D re
centers because of differences in prescription doses (see text).
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All centers showed a small advantage for autoVMAT in median
bladder Dmean (0.5 Gy–1.5 Gy) which was (borderline) significant
in centers A–C. Although overall there was no statistically signifi-
cant difference in bladder V65Gy, a small (0.7%) but significant
advantage for manVMAT was observed in center A. Table 1 pre-
sents an overview of all center-specific differences in plan
parameters.
Inter-patient variations in advantages of autoplanning were
large (Fig. 1 and Table 1). Considering all evaluation patients
improvements in rectum Dmean and V60Gy ranged from 3.7 to
12.2 Gy and from 2.3% to 15.0%, respectively. While in center D
these ranges were as large as [0.2,12.2] Gy and [2.3,15.0]%, in
center B they were only [0.8,4.9] Gy and [0.2,5.4]%, respectively.
All manVMAT and 98% of autoVMAT plans were considered
clinically acceptable. The clinicians’ scores in Table 2 reflect the
observed overall superiority of autoVMAT in dosimetric plan
parameters. Independent of the clinician considered for center D
in 29 of 80 comparisons autoVMAT was preferred with a high
impact difference with manVMAT (last column Table 2). On the
other hand, only in 6–9 comparisons the manVMAT plan was con-
sidered superior with high impact. Low impact preferences for
autoVMAT and manVMAT were similar. Clinicians’ preferences
for autoplanning were center specific (compare columns ‘A’, ‘B’,
‘C’ and ‘D1/D2’ in Table 2), in line with the observed differencesnning (manVMAT) and autoplanning (autoVMAT) in PTV V95% (a), rectum Dmean (b),
present the participating centers. Not all dosimetric parameters were relevant for all
terial planning for Volumetric Modulated Arc Therapy – An international
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Table 1
Plan parameters for manually generated VMAT plans (manVMAT) and differences with automatically generated plans (autoVMAT).
Para-meter A B C D
PTV V95%
[%]
manVMAT 99.4
[98.4,100]
99.7
[97.1,100]
94.8
[92.4,98.2]
97.7
[94.9,99.3]
manVMAT-autoVMAT 0.3
[1,2,1.2]
0.02
0.4
[1,8,2.1]
0.05
1.0
[4.0,2.7]
0.08
0.8
[1,6,3.6]
0.01
D98%
[Gy]
manVMAT 72.8
[72.4,73.2]
74.9
[73.5,75.7]
55.5
[53.6,57.3]
75.6
[73.7,76.9]
manVMAT-autoVMAT 0.3
[0.8,0.9]
0.02
0.1
[0.8,1.7]
0.1
0.5
[3.6,0.9]
0.006
0.3
[1.3,1.9]
0.1
D2%
[Gy]
manVMAT 78.2
[77.8,78.5]
81.0
[80.4,82.0]
62.1
[61.3,63.3]
81.6
[80.7,83.7]
manVMAT-autoVMAT 0.4
[1.0,0.0]
<0.001
0.1
[0.5,0.9]
0.9
0.2
[1.0,0.6]
0.2
0.0
[1.9,2.2]
0.6
HI
[%]
manVMAT 7.2
[6.2,7.9]
7.8
[6.6,9.2]
11.4
[7.2,13.7]
7.6
[6.2,10.0]
manVMAT-autoVMAT 0.1
[2.3,1.1]
0.1
0.4
[2.3,1.1]
0.2
1.4
[2,1,5.9]
0.009
0.2
[4.8,2.0]
0.4
Rectum Dmean
[Gy]
manVMAT 39.7
[30.0,45.6]
36.7
[26.9,46.3]
27.6
[21.1,33.7]
46.5
[31.3,56.3]
manVMAT-autoVMAT 5.6
[0.9,11.4]
<0.001
2.8
[0.8,4.9]
<0.001
0.1
[3.7,3.3]
0.7
8.0
[0.2,12.2]
<0.001
V60Gy
[%]
manVMAT 22.9
[16.2,37.8]
19.4
[12.0,33.0]
NA 30.7
[16.2,42.4]
manVMAT-autoVMAT 4.4
[0.9,7.7]
<0.001
2.6
[0.2,5.4]
<0.001
NA 8.7
[2.3,15.0]
<0.001
V75Gy
[%]
manVMAT NA 6.0
[1.9,11.9]
NA 9.5
[4.0,14.1]
manVMAT-autoVMAT NA 1.5
[0.7,2.2]
0.002
NA 1.5
[3.5,6.7]
0.03
Bladder Dmean
[Gy]
manVMAT 31.4
[14.5,48.9]
21.0
[7.3,43.7]
34.3
[10.7,46.3]
44.3
[15.0,55.3]
manVMAT-autoVMAT 1.0
[5.7,9.0]
0.06
0.8
[2.6,4.5]
0.07
1.5
[1.8,7.3]
0.006
0.5
[10.1,10.0]
0.4
V65Gy
[%]
manVMAT 12.4
[4.4,27.4]
7.8
[2.5,22.6]
NA 28.5
[6.2,42.5]
manVMAT-autoVMAT 0.7
[4.5,0.1]
<0.001
0.5
[2.4,3.5]
0.2
NA 0.1
[14.7,15.1]
0.9
A, B, C and D are the centers participating in this study. Population median values and ranges are reported for manVMAT. Differences with autoVMAT are characterized by
population median values (upper), ranges (middle), and p-values (lower). HI = homogeneity index. NA = Not Applicable, i.e. values were clinically insignificant because of dose
prescription.
Table 2
Blinded side-by-side comparisons of manually generated plans (manVMAT) with automatically generated plans (autoVMAT).
Center
A B C D1/D2 Centers combined
autoVMAT better – impact high 14 6 0 9/9 29/29
– impact low 3 4 6 4/1 17/14
equal plan quality 2 5 5 2/2 14/14
manVMAT better – impact low 0 1 8 5/5 14/14
– impact high 1 4 1 0/3 6/9
total 20 20 20 20 20/20 80/80
Numbers represent numbers of plan comparisons. Scoring was performed using visual analog scales presented in Fig. E3b of the Supplementary material. A, B, C, and D are the
participating centers. In center D, two clinicians compared the plans.
4 Multi-center validation of multi-criterial autoplanningin dosimetric parameters (Table 1). The treating clinicians in cen-
ters A and D preferred more frequently autoVMAT than their col-
leagues in centers B and C, following the large rectum dose
reductions with autoVMAT in the former centers (Table 1).
With autoVMAT the median modulation degree increased from
2.6 to 3.4 with median increases of 13% in MU and 6% in treatment
time (Table 3). Larger reductions in rectum Dmean and rectum V60GyPlease cite this article in press as: Heijmen B et al. Fully automated, multi-cri
multi-center validation for prostate cancer. Radiother Oncol (2018), https://dowere accompanied by larger increases in MU; p < 0.001 and R2 =
0.3 for Dmean, and p = 0.001 and R2 = 0.2 for V60Gy. In center A the
modulation degree was considerably higher than in the other cen-
ters due to the use of flattening-filter-free treatments.
QA measurements with the Delta4 system showed a minimum
pass rate for autoVMAT plans as high as 98.9%, with clinical accep-
tance criteria: 90% pass for 3%/3 mm.terial planning for Volumetric Modulated Arc Therapy – An international
i.org/10.1016/j.radonc.2018.06.023
Table 3
Modulation degree, monitor units (MU) and estimated treatment times for manually generated VMAT plans (manVMAT), and differences with automatically generated plans
(autoVMAT).
Parameter A B C D Centers combined
Modulation degree manVMAT 4.5/[2.8,5.5] 2.4/[1.6,5.0] 2.7/[2,4.1] 2.0/[1.4,2.7] 2.6/[1.4,5.5]
manVMAT-autoVMAT 0.2/[1.2,0.7]
0.09
0.7/[1.5,0.6]
0.001
0.7/[1.6,0.6]
<0.001
0.6/[1.0,0.1]
<0.001
0.6/[1.6,0.7]
<0.001
MU manVMAT 803/[543,1070] 373/[291,485] 725/[548,1100] 535/[440,798] 596/[291,1100]
manVMAT-autoVMAT 61/[289,245]
0.02
27/[74,81]
0.06
218/[656,45]
<0.001
95/[234,103]
0.002
79/[656,245]
<0.001
Treatment time [sec] manVMAT 53/[44,65] 61/[54,71] 132/[127,200] 106/[91,165] 81/[44,200]
manVMAT-autoVMAT 5/[12,0]
<0.001
2/[7,6]
0.1
13/[26,12]
<0.001
12/[27,39]
0.1
5/[27,39]
<0.001
A, B, C, and D are the centers participating in this study. Median values/ranges are reported for manVMAT.
Differences with autoVMAT are characterized by median value/range (upper) and p-value (lower).
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In this large multi-center validation of aprioriMCO for prostate
cancer autoVMAT plans were compared to plans that were manu-
ally generated in clinical routine in four European centers. There
was an overall preference for autoVMAT with important treatment
center- and patient-specific variations in the gain with autoVMAT,
the latter pointing at inconsistencies in manual planning. Fig. 1b
and 1c imply that (large) reductions in rectum Dmean with auto-
VMAT were not at the cost of important increases in rectum
V60Gy. On the contrary, reductions in Dmean were accompanied with
reductions in V60Gy (linear regression analysis; p < 0.001, R2 = 0.59).
In centers A, B, and D, large reductions in rectum doses with
autoVMAT were observed. In these centers the prescribed tumor
dose was 75 Gy and wish-list configuration was highly focused
on reducing (high) rectum dose with autoplanning. Center C did
not show significant reductions in rectum dose, probably related
to the relatively low prescribed tumor dose (60 Gy) for the investi-
gated treatment plans.
Although centers A, B and D had similar high PTV prescription
doses, the advantage of autoVMAT as expressed both in plan
parameters (Table 1) and clinician scoring (Table 2) was clearly
highest for A and D. Possibly the planners in center B were often
able to manually generate plans close to optimality for the local
treatment tradition. Besides, center B had very strict PTV coverage
restrictions; even a small reduction in coverage to obtain a large
gain in rectum dose was often not considered advantageous, reduc-
ing the potential gain of autoplanning. Other possible explanations
for the lower impact of autoplanning in center B could be the use of
a rectal balloon, or suboptimal wish-list tuning in the center.
The two autoVMAT plans that were not clinically acceptable
had too high bowel dose, related to absence of bowel delineations
other than rectum, prohibiting bowel dose optimization with the
inverse planning. A solution could be to delineate for all patients
bowel parts potentially at risk for high dose. Alternatively, in the
rare cases resulting in unacceptable bowel dose, manual fine-
tuning of the autoVMAT plan, based on an added bowel contour,
could be used to reduce bowel dose. None of these two approaches
were investigated in this study. The two clinically unacceptable
autoVMAT plans were in the group of autoVMAT plans that were
scored inferior compared to manVMAT, with considered high
impact (last column Table 2). In the other cases with high impact
advantage for manVMAT, a reduction in OAR dose (generally rec-
tum) with autoVMAT was not considered high enough to justify
a (still acceptable) loss in PTV coverage.
The observed increases in modulation degree, MU, and treat-
ment time with autoVMAT in centers A, B, and D would also have
been favored in manual planning if there would have been similar
dosimetric improvements. Apparently the manual planning
processes did not result in this enhanced quality. In center C thePlease cite this article in press as: Heijmen B et al. Fully automated, multi-cri
multi-center validation for prostate cancer. Radiother Oncol (2018), https://doconsiderable increase in MU did not result in increased plan qual-
ity. No explanation was found for this observation. It was not con-
sidered an important problem in the center as the increase in
treatment time (11 s on 146 s) was small.
At Erasmus MC Cancer Institute automated plan generation
with the investigated aprioriMCO system is in clinical routine since
2013, starting with head and neck cancer (300 patients in 2013).
The system is now in routine clinical use for head and neck, pros-
tate, cervix, and advanced lung cancer. QA measurements with the
Octavius phantom (PTW, Freiburg, Germany) with c-evaluation
acceptance criteria 90% pass for 3%/3 mm do occasionally point
at deliverability issues for head and neck cancer patients, not for
prostate. In a recent paper on liver SBRT we have reported very
high passing rates for plans with high degrees of modulation
(4.0 ± 0.9) using the same aprioriMCO system [18]. The dosimetric
measurements performed in this study confirmed deliverability of
automatically generated prostate plans. However, certainty on
deliverability for future individual patients in a clinical setting
requires measurements for each patient independent of the system
used for plan generation.
In all published studies on autoplanning for prostate cancer
[2,13], differences between automatically and manually generated
plans were small, mostly showing advantages of autoplanning in
some parameters and disadvantages for others. The overall
reported advantage of autoplanning is the large reduction in plan-
ning time. In eight of the twelve reported studies autoplanning was
knowledge-based [2,3,4,5,7,8,10,13]. In these studies the small dif-
ferences in plan quality might be related to the rather direct link of
automatically generated plans with manually generated training
plans in a busy clinical routine. Moreover, with knowledge-based
systems there is no mechanism to ensure that final plans are (close
to) Pareto-optimal. Also in studies [9,11,12], Pareto-optimality was
not guaranteed. Detailed comparison of the performed studies is
challenging because of differences in set-up: closed-loop vs.
open-loop, manual planning in clinical routine or by an expert
planner (without time constraints), autoplanning driven by a con-
figuration developed with plans of the same institute or of a differ-
ent institute, large differences in prescribed tumor dose (50–80
Gy), participating centers may or may not be all academic, large
differences in planning goals, constraints and evaluation parame-
ters, and large differences in included patients (only 2 published
studies had >50 patients included).
As described in the Introduction section the previously reported
multi-center autoplanning validation for prostate cancer by Schu-
bert et al. [10] showed very small differences between auto- and
manual planning. The design of that study was very different from
our set-up. They used a knowledge-based autoplanning system
that has no inherent drive to exceed the quality of the best man-
VMAT plans used for training, opposed to the aprioriMCO approach
used in our study. Their DVH-prediction model for autoplanningterial planning for Volumetric Modulated Arc Therapy – An international
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6 Multi-center validation of multi-criterial autoplanningwas generated in a single center and used for autoplanning in six
other centers. In contrast in our study separate autoplanning con-
figurations were performed for each center to maximally exploit
the potential of autoplanning for that center. Another difference
between the study desccribed in [10] and the current study is in
the nature of participating centers. While in the former study both
academic institutes and departments of regional community hos-
pitals or of private networks of hospitals participated, in our study
only academic centers were included. As for all published studies, a
limitation of this study was that all manual plans were generated
with a single TPS. Possibly plan quality differences could be differ-
ent for manual plans generated with a different TPS.
This large multi-center study has demonstrated overall superi-
ority of autoVMAT prostate plans compared to manVMAT plans
generated in clinical routine. Large variations between patients in
the gain of autoVMAT pointed at inconsistencies in manual plan-
ning. Superiority of autoVMAT was demonstrated with dosimetric
plan parameters and with blinded side-by-side plan comparisons
by clinicians, the latter simultaneously considering all trade-offs
in the two plans. The observed gain with autoplanning for prostate
cancer was overall larger than reported in the literature. More
research is needed to explore the full potential of autoplanning
and its optimal clinical application.
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